SEC Filings

SEC Filings

Filing date	Description	Form	View
Apr 20, 2018	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001104659-18-025614.pdf 0001104659-18-025614.rtf 0001104659-18-025614.xls
Aug 10, 2018	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001104659-18-051206.pdf 0001104659-18-051206.rtf 0001104659-18-051206.xls
Sep 20, 2018	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001104659-18-057809.pdf 0001104659-18-057809.rtf 0001104659-18-057809.xls
Jul 26, 2019	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001558370-19-006414.pdf 0001558370-19-006414.rtf 0001558370-19-006414.xls
Oct 31, 2022	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001104659-22-112950.pdf 0001104659-22-112950.rtf 0001104659-22-112950.xls
Jan 05, 2024	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	View HTML 0001104659-24-001796.pdf 0001104659-24-001796.rtf 0001104659-24-001796.xls
Sep 08, 2016	Proxy soliciting materials. Revised preliminary material	PRER14A	View HTML 0001193125-16-705153.pdf 0001193125-16-705153.rtf 0001193125-16-705153.xls
Aug 24, 2017	Proxy soliciting materials. Revised preliminary material	PRER14A	View HTML 0001047469-17-005379.pdf 0001047469-17-005379.rtf 0001047469-17-005379.xls
Jul 21, 2006	REGDEX	REGDEX	View HTML
Feb 13, 2008	REGDEX	REGDEX	View HTML 9999999997-08-007009.pdf 9999999997-08-007009.rtf

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE